



UNIVERSITY OF LEEDS

This is a repository copy of *Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/148997/>

Version: Supplemental Material

Article:

Gul, HL, Eugenio, G, Rabin, T et al. (5 more authors) (2020) Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes. *Rheumatology*, 59 (3). kez330. pp. 613-621. ISSN 1462-0324

<https://doi.org/10.1093/rheumatology/kez330>

© 2019, The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an author produced version of an article published in *Rheumatology*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Supplementary material:

T-cell subset: staining, flow cytometry strategies and reported frequencies

Subset quantification was performed for naïve, IRC and Treg cells. Flow cytometry was performed on 6 ml of fresh EDTA blood, using NHS-routine immunology services. Flow cytometry was performed as previously described[1]. Briefly, naïve and IRC CD4+T-cell subsets were identified based on their expression of CD45RB-FITC (antibody clone details in **Table S1**), CD45RA-PE and CD62L-APC. Treg were quantified by cell surface staining for CD4-Pacific blue, CD25-APC and CD127-PE followed by intracellular staining for FOXP3-FITC using the anti-human Foxp3 staining kit (Insight Biotechnology, Wembley, UK).

Staining was performed according to the NHS- routine procedures which were similar to that used previously in the research laboratory, but using 250 ul of blood per panel. Flow cytometry analysis was performed on a QUANTO cytometer (BD), using BD Biosciences FACSDIVA software. The gating strategies are presented in **Figure S1a**.

Subset frequencies were recorded as percentage of gated CD3+/CD4+ T-cells. There is an age relationship between naïve and Treg frequencies as shown in **Figure S1b**. For naïve and Treg, subset frequencies were then corrected for age as previously described [1] and reported as age corrected % of CD4+T-cells using the healthy control range: [Age corrected %] = [frequency observed in patient] - [frequency expected at that age]. The latter being calculated from the age-subset frequency correlation observed in 120 HC. This is not a statistical correction but a practical variable normalisation using positive vs negative parameter rather than a percentage value. We have changed this to normalised %: [Normalised %] = [frequency observed in patient] - [frequency expected at that age].

T-cell subset: no difference between cs-DMARDs and b-DMARDs

T-cell subset data were analysed with respect to drug intake (**Figure S2a**). There was no significant difference between groups for any of the subsets.

Glucocorticoid data were not recorded in this cohort. Previous data on early, DMARD naïve RA at inclusion into our register showed no effect previous glucocorticoid on any of the T-cells subsets (**Figure S2b**).

Reference

1. Ponchel F, Goëb V, Parmar R, et al. An immunological biomarker to predict MTX response in early RA. *Annals of the rheumatic diseases* 2014;73(11):2047-53.

Table 1S: Antibody clones used for each panel.

| Panel 1: naïve and IRC | Clone | company |
|------------------------|-------------|----------|
| CD4-BV421 | RPA-T4 | BD |
| CD3-V500 | UCHT1 | BD |
| CD45RB-FITC | MEM-55 | Serotec |
| CD45RA-PE | F8-11-13 | Serotec |
| CD62L | 130-091-755 | Miltenyi |
| Panel 2: Treg | | |
| CD4-BV421 | RPA-T4 | BD |
| CD3-V500 | UCHT1 | BD |
| CD25-Pe-Cy7 | 2A3 | BD |
| FOXP3-AF488 | 236/E7 | BD |
| CD127- PERCP-Cy5.5 | M21 | BD |






Figure S1: Flow cytometry analysis. **a)** Representative flow cytometry plot for naïve (red circle, CD45RB^{high}/CD45RA⁺/CD62L⁺), IRC (blue box CD45RA⁺/CD62L⁻) and T-reg (green box FoxP3⁺/CD25⁺/CD127⁻) following gating on CD3⁺CD4⁺ T-cells. Difference between health and RA are highlighted for naïve/IRC subsets. **b)** established age relationship in 120 healthy controls for naïve and Treg CD4⁺T-cells. [expected naïve] = $-0.63 \times [\text{age}] + 66.6$ ($\rho=0.850$, $p<0.0001$); [expected Treg] = $+0.061 \times [\text{age}] + 1.83$ ($\rho=0.554$, $p=0.001$). IRC were not related to age. IRC were considered high when above the 95% CI of distribution (set at 4%). **c)** Data from RA patient in clinical remission (naïve/IRC, n=297; Treg n=260). Lines represent expected values for naïve and Treg cell with respect to age (i.e. as in HC in panel b) and the top 95% CI of the HC distribution for IRC.




Figure S2: T-cell subset frequencies. a) Subsets frequencies in patients in DAS-remission displayed with respect to drugs : B: b-DMARDs and CS: cs-DMARDs) b) Subsets frequencies in early inflammatory arthritis patients, DMARDs-naive (n=154) displayed with respect to glucocorticoid (yes n=41 / no n=113) being used prior to the subset being tested. No significant difference was observed for either comparison.